Anna Kress, MD
Assistant Professor of Medicine (Hematology)Cards
About
Research
Publications
2023
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
Zayac A, Landsburg D, Hughes M, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Epperla N, Bond D, Farooq U, Saad M, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Advances 2023, 7: 6381-6394. PMID: 37171397, PMCID: PMC10598493, DOI: 10.1182/bloodadvances.2023009731.Peer-Reviewed Original ResearchConceptsProgression-free survivalMulti-institutional retrospective studyHigh-grade B-cell lymphomaOverall survivalB-cell lymphomaComplete responseMYC rearrangementRetrospective studyBCL6 rearrangementsGerminal center B-cell immunophenotypeHigh serum lactate dehydrogenaseHigh-risk clinical factorsBetter progression-free survivalIntensive chemotherapy programsPoor performance statusStage IV diseaseFirst-line regimensMain prognostic factorsDose-intense chemotherapyHigh-grade morphologic featuresSerum lactate dehydrogenaseB-cell immunophenotypeDA-EPOCHR-CHOPMost patientsWarm autoantibodies mimicking alloantibodies: Three cases of autoantibodies with unusual antigenic specificity
Jacobs J, Binns T, Abels E, Campos J, Elkabbani R, Kress A, Sostin N, Tormey C. Warm autoantibodies mimicking alloantibodies: Three cases of autoantibodies with unusual antigenic specificity. American Journal Of Clinical Pathology 2023, 160: 561-565. PMID: 37598315, DOI: 10.1093/ajcp/aqad095.Peer-Reviewed Original ResearchConceptsWarm autoantibodiesRed blood cellsAntigenic specificityCase of autoantibodiesCase 1Autoimmune hemolytic anemiaDirect antiglobulin testRBC transfusionPregnant womenTransfusion reactionsAntiglobulin testHemolytic anemiaAutoantibodiesRBC antigensAntibody detectionRBC unitsRare reportsBlood cellsCase 2Immunohematologic testingSignificant hemolysisRhD typingCase 3AlloantibodiesAutoanti
2022
Postibrutinib relapse outcomes for patients with marginal zone lymphoma
Epperla N, Zhao Q, Chowdhury S, Shea L, Moyo T, Reddy N, Sheets J, Weiner DM, Geethakumari P, Kandarpa M, Bruno X, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan XC, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Oh TS, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover N, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Postibrutinib relapse outcomes for patients with marginal zone lymphoma. Blood Advances 2022, 7: 88-91. PMID: 36269847, PMCID: PMC9827027, DOI: 10.1182/bloodadvances.2022008634.Peer-Reviewed Original ResearchPredictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study. Journal Of Hematology & Oncology 2022, 15: 96. PMID: 35842643, PMCID: PMC9287914, DOI: 10.1186/s13045-022-01316-1.Peer-Reviewed Original ResearchConceptsMarginal zone lymphomaRefractory marginal zone lymphomaMulticenter cohort studyPrimary refractory diseaseOverall response rateStable diseaseCohort studyComplex cytogeneticsRefractory diseaseFirst-line therapyHigh-risk subsetType of therapyProgression of diseaseInferior OSInferior PFSMedian PFSPartial responsePredictive factorsExperimental therapiesStudy populationEligibility criteriaClinical practicePatientsResponse rateIbrutinib
2017
Therapeutic Options for Aggressive T-Cell Lymphomas.
Lue JK, Kress A, Amengual JE. Therapeutic Options for Aggressive T-Cell Lymphomas. Current Hematologic Malignancy Reports 2017, 12: 269-281. PMID: 28573497, DOI: 10.1007/s11899-017-0389-7.Peer-Reviewed Original Research
Clinical Care
Overview
Anna Kress, MD, is a medical oncologist and hematologist who cares for people with B-cell lymphomas (cancers that affect specific white blood cells) and nonmalignant blood disorders.
As an assistant professor of medicine (hematology) at Yale School of Medicine, Dr. Kress research focused on advancing treatments for lymphomas and blood diseases.
Dr. Kress received her medical degree from Columbia University Vagelos College of Physicians and Surgeons, then completed her internship and residency in internal medicine at Columbia University Medical Center, NewYork-Presbyterian Hospital. She later pursued a fellowship in medical oncology and hematology at Yale New Haven Hospital.
Clinical Specialties
Hematology; Hematologic Oncology
Fact Sheets
Non-Hodgkin's Lymphoma
Learn More on Yale MedicineDeep Vein Thrombosis
Learn More on Yale MedicineBlood Clots in Veins, Heart and Lungs
Learn More on Yale MedicineDiffuse Large B-Cell Lymphoma
Learn More on Yale Medicine
Board Certifications
Hematology (Internal Medicine)
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2022
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2019
Yale Medicine News
News
Get In Touch
Contacts
Email
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.